Pegvisomant: complete guide

Pegvisomant is a growth hormone receptor antagonist first approved by FDA as Somavert in 2003. This guide covers its structure, mechanism, labeled use, trials and warnings.

Complete guide5 min read

Key takeaway

FDA first approved pegvisomant as Somavert on March 25, 2003. Its protein part has 191 amino acids, with nine changes from natural growth hormone. In the pivotal 12-week human trial, IGF-1 normalized in up to 89% of treated patients, versus 10% with placebo.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Drugs@FDA lists the original approval of Somavert on March 25, 2003.” (this article)
ClassGrowth hormone axis
Body systemsEndocrine & metabolism
Studies cited2 in this article · 2 across 1 article on Pegvisomant
Related productsGHRH analogs and GH secretagogues

Pegvisomant is a growth hormone receptor antagonist: a modified copy of human growth hormone that sits on the receptor without switching it on. It is used to lower IGF-1 in acromegaly. This guide covers its structure, mechanism, FDA-labeled use, key trials and label warnings. Sources were checked on November 17, 2026.

Quick answer: Pegvisomant is a prescription drug sold as Somavert. Its label covers acromegaly in patients who had an inadequate response to surgery or radiation, or for whom those therapies are not appropriate. It blocks growth hormone receptors so the body makes less IGF-1. The label has no boxed warning and no contraindications.

Vitrapep does not sell pegvisomant; this page is a reference summary of published research and regulatory information.

What is pegvisomant?

Pegvisomant is a growth hormone (GH) analog built to block, not activate, the GH receptor. The Somavert label says the protein “contains 191 amino acid residues.” It lists nine amino acid substitutions relative to human GH, such as glycine 120 changed to lysine. Chains of polyethylene glycol (PEG) are attached at several sites, mostly lysines (Somavert label, 2023). PEG is a synthetic polymer, and attaching it is called PEGylation.

The label gives the protein a molecular weight of 22 kDa and each PEG chain about 5 kDa. Because the number of PEG chains varies, the main forms weigh about 42, 47 and 52 kDa. It is made in Escherichia coli bacteria carrying a gene for the GH receptor antagonist.

Is it a peptide? Its core is a single polypeptide chain. At 191 amino acids, FDA rules class it as a protein, which means more than 40 amino acids (21 CFR 600.3). Our peptide vs protein explainer covers that line. PubChem has no compound record for pegvisomant, so no molecular formula is given here.

Drugs@FDA lists the original approval of Somavert on March 25, 2003, with Pharmacia as the company. The record notes: “This Former NDA Was Deemed To Be a BLA on March 23, 2020” (Drugs@FDA). FDA had granted it orphan drug designation for acromegaly on June 24, 1997 (FDA orphan drug database).

Table 1

Pegvisomant: key facts

Fact Detail
Structure type 191-amino-acid GH analog with nine substitutions, carrying several PEG chains
Class Growth hormone receptor antagonist (biologic)
Molecular formula No PubChem compound record; not stated in the label
Molecular weight Protein 22 kDa; PEGylated forms about 42, 47 and 52 kDa (Somavert label)
First FDA approval March 25, 2003 (Somavert, BLA 021106, originally an NDA)
Brand names (US) Somavert (Pharmacia & Upjohn)

How does pegvisomant work?

Acromegaly is a disorder of excess GH, which drives high IGF-1. Pegvisomant interrupts that signal at the receptor. The label states that it “selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH.” This “interferes with GH signal transduction” (Somavert label, 2023).

With GH action blocked, IGF-1 falls. The label adds that free IGF-1, the acid-labile subunit and IGF binding protein 3 also fall. Somatostatin analogs such as octreotide and pasireotide work upstream, by lowering GH release. Pegvisomant is the mirror image of somatropin, which activates the same receptor.

What is pegvisomant approved for?

The Somavert label covers acromegaly “in patients who have had an inadequate response to surgery or radiation therapy.” It also covers patients “for whom these therapies are not appropriate.” It adds: “The goal of treatment is to normalize serum insulin-like growth factor-1 (IGF-1) levels.”

What did the key trials show?

Pivotal trial. A randomized, double-blind, multicenter human trial enrolled 112 patients with acromegaly for 12 weeks. It compared placebo with three pegvisomant groups. Mean IGF-1 fell 4.0% with placebo and 26.7%, 50.1% and 62.5% in the three treated groups. IGF-1 became normal in 10% of placebo patients. In the treated groups the rates were 54%, 81% and 89% (Trainer et al., 2000). The label reports the same trial and says all three treated groups had significant IGF-1 reductions versus placebo (p<0.01).

Longer-term treatment. A follow-up human study analyzed 160 patients for safety and 152 for efficacy, with treatment for up to 18 months. Of 90 patients treated for 12 months or more, 87 (97%) reached a normal IGF-1. Mean pituitary tumor volume did not change significantly in 131 patients, though 2 had tumor growth. Two patients stopped because of raised liver enzymes. Antibodies to GH appeared in 27 patients (16.9%), without loss of effect (van der Lely et al., 2001).

The label also reports an open-label extension. There, 100 of 108 subjects (92.6%) with IGF-1 data had a normal IGF-1 at some visit.

What side effects does the label list?

The Somavert label has no boxed warning, and its contraindications section reads “None.” Its highlights list the most common reactions, reported in more than 6% of patients:

  • infection, pain and flu syndrome;
  • nausea and diarrhea; and
  • abnormal liver tests.

The warnings cover five areas. The first is low blood sugar when GH is lowered in patients with diabetes. The others are liver toxicity, cross-reactivity with GH lab tests, lipohypertrophy and systemic hypersensitivity. The label sets IGF-1, not GH, as the treatment goal (Somavert label, 2023).

What is pegvisomant’s regulatory status, and how is it used in research?

Pegvisomant is a prescription biologic in the United States. Its original NDA was deemed a biologics license application on March 23, 2020. The FDA orphan drug database lists orphan exclusivity that ended on March 25, 2010. DailyMed lists one label, Somavert from Pharmacia & Upjohn (DailyMed, 2026).

Pfizer has registered further studies, including a comparison with octreotide (Sandostatin LAR) that lists 100 participants (NCT00068042). The research summarized here is clinical: human trials in acromegaly.

Frequently asked questions about pegvisomant

Is pegvisomant a peptide?

Its core is a 191-amino-acid polypeptide with PEG chains attached. Because it has more than 40 amino acids, FDA rules class it as a protein.

Is pegvisomant a growth hormone?

It is a modified GH molecule, but it blocks the GH receptor instead of activating it. Its effect is the opposite of growth hormone.

When was pegvisomant approved?

Drugs@FDA lists the original approval of Somavert on March 25, 2003.

Why is IGF-1 the target and not GH?

The label sets normal IGF-1 as the goal of treatment. It also warns that pegvisomant can cross-react with GH assays.

Does pegvisomant have a boxed warning?

No. Its warnings include liver toxicity, low blood sugar in patients with diabetes and hypersensitivity.

What to know now

  • Structure: 191-amino-acid GH analog with nine substitutions and attached PEG chains.
  • Approval: Somavert, March 25, 2003; deemed a biologic in 2020; prescription only.
  • Mechanism: blocks GH receptors, so IGF-1 falls.
  • Evidence: IGF-1 normalized in up to 89% at 12 weeks versus 10% with placebo; 97% in longer-term follow-up.
  • Safety: no boxed warning; liver tests and GH assay cross-reactivity are key warnings.

What we’re watching

Further Somavert label revisions on DailyMed, last revised in July 2023. Related guides: somatropin, pasireotide and lanreotide.

More for endocrine & metabolism

All 38 compounds for endocrine & metabolism

Sources: Pharmacia & Upjohn Company LLC 2023, SOMAVERT (pegvisomant) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: BLA 021106 (SOMAVERT) . Retrieved November 17, Drugs@FDA: BLA 021106 (SOMAVERT); U.S. Food and Drug Administration. Search orphan drug designations and approvals: pegvisomant (Somavert) . Retrieved November 17, Search orphan drug designations and approvals: pegvisomant (Somavert); Trainer 2000, The New England Journal of Medicine, 342; van der Lely 2001, The Lancet, 358; Pfizer 2003; U.S. National Library of Medicine 2026, DailyMed SPL listing: pegvisomant; Legal Information Institute. 21 CFR &sect; 600.3: Definitions . Cornell Law School. Retrieved November 17, 21 CFR &sect; 600.3: Definitions. All 8 citations

Back to the research library

References

  1. Pharmacia & Upjohn Company LLC. (2023). SOMAVERT (pegvisomant) prescribing information (revised 7/2023). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3cbb485b-6df1-49ce-8747-592b395b1988
  2. U.S. Food and Drug Administration. Drugs@FDA: BLA 021106 (SOMAVERT). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021106
  3. U.S. Food and Drug Administration. Search orphan drug designations and approvals: pegvisomant (Somavert). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=105097
  4. Trainer, P. J., et al. (2000). Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. The New England Journal of Medicine, 342(16), 1171-1177. https://doi.org/10.1056/NEJM200004203421604
  5. van der Lely, A. J., et al. (2001). Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. The Lancet, 358(9295), 1754-1759. https://doi.org/10.1016/s0140-6736(01)06844-1
  6. Pfizer. (2003). A study to compare the efficacy and safety of pegvisomant to that of Sandostatin LAR Depot in patients with acromegaly (ClinicalTrials.gov ID NCT00068042). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT00068042
  7. U.S. National Library of Medicine. (2026). DailyMed SPL listing: pegvisomant. Retrieved November 17, 2026, from https://dailymed.nlm.nih.gov/dailymed/services/v2/spls.json?drug_name=pegvisomant
  8. Legal Information Institute. 21 CFR § 600.3: Definitions. Cornell Law School. Retrieved November 17, 2026, from https://www.law.cornell.edu/cfr/text/21/600.3